# CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer

> **NCT00932724** · PHASE2 · TERMINATED · sponsor: **Cytavis Biopharma GmbH** · enrollment: 77 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** CY-503
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00932724
- **Lead sponsor:** Cytavis Biopharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** The sponsor declared the early termination of the study due to poor recruitment of patients.
- **Last updated:** 2013-07-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932724, "CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00932724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*